Clinical trial
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer…
NCT00006028 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006028 |
|---|---|
| Title | Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy |
| Official title | Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gemcitabine hydrochloride |
| Start date | Jan 1, 2001 |
| Primary completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | May 27, 2013 |
| Countries | Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: